Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ESMO E-Learning: Treatment of Advanced Cervical Carcinoma

New E-Learning module by Dr Susanna Banerjee, Dr Shira Peleg Hasson and Dr Elli-Sophia Tripodaki is now available. Watch the presentation and take the CME test today!

ESMO members

Take the CME test and receive

1 ESMO - MORA point

77 slides / 56 minutes

Learning objectives

  • To provide an introduction to incidence, epidemiology and prevention of cervical cancer
  • To provide a summary of staging for cervical cancer and related considerations
  • To provide an update of treatment options and treatment algorithms in patients with recurrent/metastatic cervical cancer


In this E-Learning module the authors elaborate the global burden of cervical cancer worldwide, explaining discrepancy in incidence and mortality between developing and developed countries, emphasizing that prevention is key and digging into primary and secondary prevention coverage and effectiveness, explain differences in revised staging, survival outcomes, deep into pivotal practice changing results of clinical studies conducted in women with advanced disease, and elaborate promising early phase approaches.

The authors underline that cervical cancer is a malignancy with the largest inter-country range of variation in mortality among all cancers, caused by differences in availability of cervical cancer screening, HPV infection prevalence and implementation of HPV vaccination.

The focus of this module is on systemic treatment in recurrent and metastatic setting. The authors made a significant effort to describe and put into context the results from the pivotal trials and show progress made in the management of women with cervical cancer. They underline that platinum/paclitaxel/bevacizumab/pembrolizumab is a new standard of care for metastatic and recurrent disease in patients with PD-L1-positive tumours and draw attention to option of replacing cisplatin with carboplatin.

The authors elaborate the findings from trials investigating antiangiogenic agents, immune checkpoint inhibitors and antibody drug conjugates that led to regulators’ approvals or where the results are expected and provide an overview of currently recruiting trials. They state that promising early approaches include T-cell receptor gene therapy, tumour infiltrating lymphocytes, and CAR T cells.

In this module, the authors also elaborate main features of cervical neuroendocrine carcinoma and explain the palliative aspects of cervical cancer care.

Last update: 01 Feb 2023

Shira Peleg Hasson has reported the following financial interests:
Invited Speaker, Personal: Roche Israel, MSD Israel;
Advisory Board, Personal: Pfizer.

Elli-Sophia Tripodaki
has no interests to declare

Susana Banerjee has reported the following financial interests:
Advisory Board, Personal: Amgen, Immunogen, Mersana, Merck Sereno, MSD, Roche, AstraZeneca, GSK, Oncxerna, Shattuck Labs, Novartis, Epsilogen, Seagen, Eisai.
Invited Speaker, Personal: Clovis, Pfizer, AstraZeneca, GSK, Takeda, Amgen, Medscape, PeerView, Research To Practice.
Research Grant, Institutional: AstraZeneca, GSK.
Stocks/Shares, Personal: Perci Health
Non-Financial Interests:
Verastem, Principal Investigator, Phase II clinical trial Global lead, ENGOTov60/GOG3052/RAMP201
AstraZeneca, Principal Investigator, ENGOT-GYN1/ATARI phase II international trial (academic sponsored)
GSK, Principal Investigator, Academic sponsored trial PI (MONITOR-UK)
ESGO, Other, Member of membership committee
Ovacome Charity, Advisory Role, Medical advisor to UK ovarian cancer charity

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.